Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James M Olson

Showing results (81-90 of 160) with videos related to

Pageof 16
Sort By:
Cancer Research|October 5, 2013
MyoD is a tumor suppressor gene in medulloblastomaJoyoti Dey, Adrian M Dubuc, Kyle D Pedro, et al.
Nature Communications|December 23, 2017
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targetsZachary R Crook, Gregory P Sevilla, Della Friend, et al.
Cancer Research|October 17, 2015
Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid TumorsJanean Fidel, Katie C Kennedy, William S Dernell, et al.
Nature Communications|March 11, 2018
Publisher Correction: Mammalian display screening of diverse cystine-dense peptides for difficult to drug targetsZachary R Crook, Gregory P Sevilla, Della Friend, et al.
Science (New York, N.Y.)|August 31, 2002
Medulloblastoma growth inhibition by hedgehog pathway blockadeDavid M Berman, Sunil S Karhadkar, Andrew R Hallahan, et al.
Human Molecular Genetics|August 8, 2002
Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effectsRuth Luthi-Carter, Andrew D Strand, Sarah A Hanson, et al.
Cancer Research|March 15, 2008
The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spreadBeryl A Hatton, Elisabeth H Villavicencio, Karen D Tsuchiya, et al.
Epigenetics|October 11, 2013
Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancerScott J Diede, Zizhen Yao, C Chip Keyes, et al.
Contemporary Clinical Trials Communications|August 17, 2021
A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patientsMiko Yamada, Dennis M Miller, Melinda Lowe, et al.
Leukemia|March 29, 2018
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulationColin E Correnti, George S Laszlo, Willem J de van der Schueren, et al.
Pageof 16

Showing results (81-90 of 160) with videos related to

Sort By:
Pageof 16
Cancer Research|October 5, 2013
MyoD is a tumor suppressor gene in medulloblastomaJoyoti Dey, Adrian M Dubuc, Kyle D Pedro, et al.
Nature Communications|December 23, 2017
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targetsZachary R Crook, Gregory P Sevilla, Della Friend, et al.
Cancer Research|October 17, 2015
Preclinical Validation of the Utility of BLZ-100 in Providing Fluorescence Contrast for Imaging Spontaneous Solid TumorsJanean Fidel, Katie C Kennedy, William S Dernell, et al.
Nature Communications|March 11, 2018
Publisher Correction: Mammalian display screening of diverse cystine-dense peptides for difficult to drug targetsZachary R Crook, Gregory P Sevilla, Della Friend, et al.
Science (New York, N.Y.)|August 31, 2002
Medulloblastoma growth inhibition by hedgehog pathway blockadeDavid M Berman, Sunil S Karhadkar, Andrew R Hallahan, et al.
Human Molecular Genetics|August 8, 2002
Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effectsRuth Luthi-Carter, Andrew D Strand, Sarah A Hanson, et al.
Cancer Research|March 15, 2008
The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spreadBeryl A Hatton, Elisabeth H Villavicencio, Karen D Tsuchiya, et al.
Epigenetics|October 11, 2013
Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancerScott J Diede, Zizhen Yao, C Chip Keyes, et al.
Contemporary Clinical Trials Communications|August 17, 2021
A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patientsMiko Yamada, Dennis M Miller, Melinda Lowe, et al.
Leukemia|March 29, 2018
Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulationColin E Correnti, George S Laszlo, Willem J de van der Schueren, et al.
Pageof 16